Avidity of anti- beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome

Antibodies against beta 2-glycoprotein I (anti- beta 2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidit...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2012-06, Vol.21 (7), p.764-765
Main Authors: Cucnik, S, Kveder, T, Artenjak, A, Gallova, Z Ulcova, Swadzba, J, Musial, J, Iwaniec, T, Stojanovich, L, Alessandri, C, Valesini, G, Avcin, T, Tervaert, JW Cohen, Rozman, B, Bozic, B
Format: Article
Language:English
Subjects:
Antibodies
antiphospholipid syndrome
Avidity
beta 2-Glycoprotein I
Epitopes
Systemic lupus erythematosus
Thrombosis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Antibodies against beta 2-glycoprotein I (anti- beta 2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti- beta 2GPI antibodies. Our results confirmed that high avidity anti- beta 2GPI are associated with thrombosis and APS, while in low avidity anti- beta 2GPI group non-APS (predominantly systemic Lupus erythematosus) patients prevailed.
ISSN:0961-2033
DOI:10.1177/0961203312440057